Cryolife Inc (NYSE:CRY) VP Jean F. Holloway Sells 8,654 Shares

Cryolife Inc (NYSE:CRY) VP Jean F. Holloway sold 8,654 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $32.00, for a total value of $276,928.00. Following the sale, the vice president now directly owns 67,020 shares of the company’s stock, valued at $2,144,640. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of CRY traded up $0.21 on Friday, reaching $28.75. The stock had a trading volume of 293,979 shares, compared to its average volume of 175,132. The stock has a market cap of $1.07 billion, a P/E ratio of 110.58 and a beta of 0.54. The company has a debt-to-equity ratio of 0.86, a current ratio of 4.90 and a quick ratio of 3.69. Cryolife Inc has a twelve month low of $23.99 and a twelve month high of $36.05.

Cryolife (NYSE:CRY) last released its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported $0.04 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.04. The business had revenue of $67.50 million for the quarter, compared to analysts’ expectations of $66.37 million. Cryolife had a positive return on equity of 3.79% and a negative net margin of 0.09%. The company’s revenue was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.02 EPS. Research analysts expect that Cryolife Inc will post 0.31 EPS for the current fiscal year.

Several equities analysts have issued reports on CRY shares. Zacks Investment Research upgraded Cryolife from a “sell” rating to a “hold” rating in a research report on Tuesday, April 23rd. ValuEngine cut Cryolife from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, May 15th. TheStreet cut Cryolife from a “b-” rating to a “c+” rating in a research report on Wednesday, May 22nd. Canaccord Genuity reiterated a “buy” rating and set a $35.00 target price (up previously from $32.00) on shares of Cryolife in a research report on Wednesday, May 1st. Finally, Needham & Company LLC started coverage on Cryolife in a research report on Wednesday, February 27th. They set a “hold” rating and a $29.65 target price on the stock. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Cryolife currently has an average rating of “Buy” and an average price target of $31.91.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC acquired a new stake in shares of Cryolife in the 1st quarter worth approximately $1,459,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Cryolife in the 1st quarter worth approximately $7,086,000. Metropolitan Life Insurance Co NY grew its holdings in shares of Cryolife by 30.6% in the 1st quarter. Metropolitan Life Insurance Co NY now owns 14,428 shares of the medical equipment provider’s stock worth $2,320,000 after acquiring an additional 3,379 shares during the period. Advisors Asset Management Inc. grew its holdings in shares of Cryolife by 75.1% in the 1st quarter. Advisors Asset Management Inc. now owns 1,965 shares of the medical equipment provider’s stock worth $57,000 after acquiring an additional 843 shares during the period. Finally, ArrowMark Colorado Holdings LLC grew its holdings in shares of Cryolife by 8.8% in the 1st quarter. ArrowMark Colorado Holdings LLC now owns 553,254 shares of the medical equipment provider’s stock worth $16,138,000 after acquiring an additional 44,748 shares during the period. Institutional investors and hedge funds own 71.44% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Cryolife Inc (NYSE:CRY) VP Jean F. Holloway Sells 8,654 Shares” was first posted by Mayfield Recorder and is owned by of Mayfield Recorder. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://mayfieldrecorder.com/2019/06/01/insider-selling-cryolife-inc-cry-vp-sells-276928-00-in-stock.html.

Cryolife Company Profile

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Read More: The risks of owning bonds

Insider Buying and Selling by Quarter for Cryolife (NYSE:CRY)

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.